DOMINION BIOTECH LTD
Dominion Biotech Ltd is a Manchester, UK-based B2B contract research organization providing patient-derived cell models, 3D tumoroids, and immunotherapy assays to pharmaceutical clients for cancer drug discovery.
- Company typePrivate
- Founded2024
- HeadquartersAlderley Park, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What DOMINION BIOTECH LTD does
Dominion Biotech Ltd is a Manchester, UK-based private limited company that provides Patient-Derived Cell (PDC) models and assays for cancer drug discovery, operating as a B2B contract research organization serving pharmaceutical and biotechnology clients. The company runs four core service lines: drug screening, 3D tumoroid models, immunotherapy testing, and stratified medicine assays, supported by an installed base of over 100 high-content screening (HCS) assays. Its technology platform is built around autologous tumor models derived from patient tissue samples, enabling functional drug response profiling in a physiologically relevant context rather than relying on generic cell lines.
The company has assembled a senior leadership team drawn from Imagen Therapeutics, PwC, and machine learning research. Under CEO Dr Anthony Holmes, the company is building a self-learning AI model to enhance assay data interpretation, indicating intent to evolve from manual assay services toward a data-driven discovery platform. The company also operates an in-house PDC biobank sourced through a network of partner cancer hospitals, providing access to diverse tissue types and mutation backgrounds that compound as additional samples are accrued.
Commercially, Dominion Biotech pursues a services-plus-data model with go-to-market through a strategic partnership with Servier, laboratory services provider Inaphaea, and outsourced R&D marketplaces Science Exchange and Scientist.com. Geographic presence is anchored in the UK with active business development in the EU and US, reflecting a deliberate transatlantic commercial push. The company is a member of OBN, indicating participation in the UK life sciences trade ecosystem, and is registered in England and Wales under company number 15417327.
DOMINION BIOTECH LTD firmographics
Firmographics- Name
- DOMINION BIOTECH LTD
- Legal name
- Dominion Biotech Limited
- Website
- https://dominionbiotech.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Dominion Biotech Ltd is a Manchester, UK-based B2B contract research organization providing patient-derived cell models, 3D tumoroids, and immunotherapy assays to pharmaceutical clients for cancer drug discovery.
- Ownership category
- akta.pro rank
DOMINION BIOTECH LTD industry classification
Industry- Product category
- Preclinical Oncology Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
- akta.pro secondary industry
- Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)
Keywords
Where DOMINION BIOTECH LTD is headquartered
LocationHeadquarters
- HQ city
- Alderley Park
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
DOMINION BIOTECH LTD business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Drug Screening Services: High-throughput drug screening services utilizing PDC biobank to test compounds against diverse cancer types and genetic profiles. Flexible options for single agent and combination therapy screening.
- 3D Tumoroid Model Services: Advanced 3D tumoroid model services for physiologically relevant drug testing in tumor-stroma interactions and drug penetration studies.
- Immunotherapy Testing Services: Immunotherapy testing using autologous PBMCs with matched tumor samples for immuno-oncology research.
- Genetic Characterization Services: Next-generation sequencing and RNA sequencing services with comprehensive bioinformatics pipeline for data interpretation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
DOMINION BIOTECH LTD product offering
Product offeringCore offering
Dominion Biotech provides patient-derived cell (PDC) assay services for cancer drug discovery, offering high-throughput drug screening, 3D tumoroid models, autologous immunotherapy testing, and stratified medicine assays to pharmaceutical companies. The services are supported by an extensive PDC biobank covering diverse tissue types and clinically relevant mutations including EGFR, BRAF, KRAS, PIK3CA, BRCA1/2, and triple negative breast cancer, combined with next-generation sequencing and RNA sequencing characterization on every sample.
Product overview
Dominion Biotech offers a unified suite of patient-derived cell (PDC) assay services for cancer drug discovery, built around four interconnected service areas. The core services include Drug Screening (high-throughput testing using their PDC biobank), 3D Tumoroid Models (advanced 3D culture systems with stromal cells), Immunotherapy Testing (autologous PBMC co-culture systems), and Stratified Medicine Assays (genetic profile-based patient stratification). These services are supported by enabling capabilities including PDC Model Development, Genetic Characterization (NGS and RNA sequencing), Assay Development & Validation (100+ HCS assays), and Data Analysis with AI & Reporting. The company operates as a service-based organization rather than a software product, providing end-to-end capabilities from sample acquisition through actionable insights, with AI-enhanced predictive analytics integrated into their data analysis workflow.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Screening
Quantifiable outcome
- Reduce late-stage clinical trial failures
- +3 more outcomes
Companies that use DOMINION BIOTECH LTD
Customer profileSegments2 records
Ideal customer profiles2 records
DOMINION BIOTECH LTD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration12 records
AI capability2 records
Feature6 records
DOMINION BIOTECH LTD partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- ServiercorePharmaceutical company partnership providing access to their drug development expertise and potential collaboration on cancer drug discovery programs. Logo displayed on partners section of website.
- InaphaeacoreLaboratory services partner providing access to additional screening capabilities and assay services. Logo displayed on partners section of website.
- Science ExchangeminorScientific services marketplace platform enabling access to Dominion Biotech services through their vendor network. Logo displayed on partners section.
- Scientist.comminorScientific services marketplace platform providing access to Dominion Biotech services. Logo displayed on partners section.
- OBN (Oxford Biotech Network)minorMembership in Oxford Biotech Network providing access to biotech community, networking, and potential collaboration opportunities. Logo displayed on partners section.
- Tissue Supplier NetworkcoreNetwork of tissue suppliers and leading cancer hospitals providing fresh tumor sample acquisition and continuous expansion of tissue types and mutations for PDC models.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
DOMINION BIOTECH LTD competitors and assessment
Company assessmentEmerging players
- Reaction Biology: US-based CRO providing cell-based assay services, including oncology and immuno-oncology screening. Comparable in offering high-throughput screening on cancer cell models for pharma partners.
- iXCells Biotechnologies: US-based CRO providing patient-derived cell models, primary cells, and cell-based assay services for drug discovery. Comparable in offering preclinical oncology screening services with PDX and PDC models.
Direct peers
- DefiniGEN: UK-based provider of human iPSC-derived cell models and organoid services for drug discovery. Shares Dominion's UK base and focus on clinically relevant cellular models for pharmaceutical research.
- Reprocell: Japan-based stem cell and drug discovery CRO with patient-derived cell models and 3D culture services. Competes with Dominion in offering clinically relevant cellular models for preclinical oncology and immuno-oncology research.
- Crown Bioscience: Global CRO providing patient-derived xenograft (PDX) and patient-derived cell models for oncology drug discovery. Directly competes with Dominion Biotech in the preclinical oncology CRO space, offering similar biobank and screening services to pharmaceutical partners.
- NewCells Biotech: UK-based CRO specializing in patient-derived organoid and cell-based models for drug discovery. Comparable to Dominion Biotech in offering physiologically relevant in vitro models for oncology and other therapeutic areas.
Regional players
- Domainex: UK-based drug discovery CRO offering integrated services including assay development and screening. Geographic peer in the UK life sciences ecosystem with overlapping oncology assay capabilities.
Broad incumbents
- Charles River Laboratories: Large global CRO with extensive preclinical oncology services including PDX models, cell-based assays, and bioanalytical services. Represents a broad incumbent competitor in the same end market though with much wider service portfolio.
- Eurofins Discovery: Large global CRO with broad preclinical services including oncology, cell-based assays, and genomic characterization. Represents a broad incumbent with overlapping capabilities in cancer drug discovery services.
Others
- Imagen Therapeutics: Predecessor company co-founded by Dominion Biotech's COO and CSO. Highly relevant reference point for understanding the playbook and commercial trajectory of the founding team, though not a current direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
DOMINION BIOTECH LTD social profiles
Digital presenceDOMINION BIOTECH LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
DOMINION BIOTECH LTD leadership team
Management profileNumber of profiles
Profiles6 records
DOMINION BIOTECH LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DOMINION BIOTECH LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DOMINION BIOTECH LTD
What does DOMINION BIOTECH LTD do?
Dominion Biotech provides patient-derived cell (PDC) assay services for cancer drug discovery, offering high-throughput drug screening, 3D tumoroid models, autologous immunotherapy testing, and stratified medicine assays to pharmaceutical companies. The services are supported by an extensive PDC biobank covering diverse tissue types and clinically relevant mutations including EGFR, BRAF, KRAS, PIK3CA, BRCA1/2, and triple negative breast cancer, combined with next-generation sequencing and RNA sequencing characterization on every sample.
Is DOMINION BIOTECH LTD a public or private company?
DOMINION BIOTECH LTD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DOMINION BIOTECH LTD founded?
DOMINION BIOTECH LTD was founded in 2024. It employs 1 to 10 people.
Where is DOMINION BIOTECH LTD based?
DOMINION BIOTECH LTD is headquartered in Alderley Park, United Kingdom, in the Europe region.
How does DOMINION BIOTECH LTD make money?
Four revenue lines are on record. Drug Screening Services are the primary driver. The others are 3D Tumoroid Model Services, immunotherapy Testing Services and genetic Characterization Services.
Who are DOMINION BIOTECH LTD's main competitors?
Emerging players on record are Reaction Biology and iXCells Biotechnologies. Direct peers are DefiniGEN, Reprocell, Crown Bioscience and NewCells Biotech. Domainex is listed as a regional player. Broad incumbents are Charles River Laboratories and Eurofins Discovery. Imagen Therapeutics is listed as an others.
Does DOMINION BIOTECH LTD have an API?
No public API is recorded for DOMINION BIOTECH LTD.
What industry is DOMINION BIOTECH LTD in?
DOMINION BIOTECH LTD's product category is Preclinical Oncology Drug Discovery Services. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays), with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.